Stocks
BMY-AZN Merger Denial Puts Pharma M&A Outlook in Focus
A Financial Times report of BMY-AZN merger talks was swiftly denied by Reuters sources, reigniting debate on Big Pharma M&A prospects. Seeking...
#astrazeneca 2 articles
Stocks
AZN’s Imfinzi Combo Wins Late-Stage Liver Cancer Trial
AstraZeneca (AZN) announced a successful late-stage trial for its Imfinzi combination regimen in a subset of liver cancer patients, bolstering the company's...